Urinary Incontinence, Stress Clinical Trial
— GladiolusOfficial title:
Group Learning Achieves Decreased Incidents of Lower Urinary Symptoms
Verified date | October 2017 |
Source | William Beaumont Hospitals |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This three-site randomized controlled trial compares the effectiveness and cost-effectiveness of a group-administered behavioral treatment program to no treatment. Women with stress, urgency, or mixed urinary incontinence will be recruited and screened centrally, evaluated clinically at each of three study sites, and random assigned to one of two treatment arms: 1. Group behavioral treatment or 2. No treatment. Group treatment modalities have the potential to reach a larger population of older women with urinary incontinence, not only in the traditional medical settings, but also in community settings. The investigators hypothesize that group behavioral treatment will be more effective than no treatment. The investigators hypothesize that the group treatment will be cost-effective compared to no treatment.
Status | Completed |
Enrollment | 463 |
Est. completion date | December 2016 |
Est. primary completion date | December 2016 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 55 Years and older |
Eligibility |
Inclusion Criteria: 1. Female 2. Aged 55 years or older 3. Ability to understand, read and write English 4. Stress, urgency, or mixed urgency and stress urinary incontinence (UI) (by self report) 5. On the International Consultation on Incontinence Modular Questionnaire - Short Form (ICIQ UI-SF), frequency of leakage at least a 1 ("about once a week or less often") on item #1 and volume of urine loss at least a 2 ("a small amount") on item #2. 6. Symptoms of three months duration or longer (on history) 7. Passing score (i.e., categorized as "probably not demented") on the MiniCog Test 8. Timed "Up and Go" Test (TUG) score of 20 seconds or less 9. Willing to undergo vaginal/pelvic examination 10. Signed informed consent form Exclusion Criteria: 1. History of renal, bladder, uterine, ovarian, urethral, anal or rectal cancer, radiation therapy to the pelvis for any cancer/malignancy, or any active cancer/malignancy (except skin cancer) 2. Non-ambulatory (participant confined to bed or wheelchair) 3. Persistent pelvic pain (defined as daily pelvic pain > 3 months) 4. History of neurologic or end-stage diseases (e.g. cerebral vascular accident (CVA), Parkinson's disease, multiple sclerosis, epilepsy, spinal cord tumor or trauma, spina bifida, symptomatic herniated disc) 5. Previous treatment or current participation in a research study for UI, including surgery or formal behavioral treatment (pelvic floor muscle training, biofeedback, pelvic floor electrical stimulation, percutaneous tibial nerve stimulation, sacral neuromodulation, botox or other periurethral injection) 6. Currently taking urinary incontinence or overactive bladder medications 7. History of other urinary conditions or procedures that may affect continence status (e.g. urethral diverticula, previous augmentation cystoplasty or artificial urinary sphincter; implanted nerve stimulators for urinary symptoms) 8. Participation in any drug/device research study. 9. Pelvic organ prolapse protruding past the introitus (at rest or persisting after strain) 10. Evidence of urinary tract infection (UTI) by urine dipstick (leukocytes +1 or greater, nitrites +1 or greater, leukocytes alone (w/o nitrites) +2 or greater, or presence of hematuria > +1). Participants may be re-screened after treatment with antibiotics or if hematuria work-up is negative. 11. History of 2 or more recurrent UTI's within the past year; more than one UTI within past 6 months 12. Post void residual urine volume 150 cc or more. 13. Unstable medical condition (as determined by site PI) |
Country | Name | City | State |
---|---|---|---|
United States | University of Michigan | Ann Arbor | Michigan |
United States | Birmingham VA Medical Cnter | Birmingham | Alabama |
United States | University of Pennsylvania Health System, Urology | Philadelphia | Pennsylvania |
United States | William Beaumont Hospital | Royal Oak | Michigan |
Lead Sponsor | Collaborator |
---|---|
Ananias Diokno | National Institute on Aging (NIA) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Group Behavioral Treatment Effectiveness as Shown by Changes From Baseline to 3 Months in Urinary Incontinence Severity. | The primary outcome is the self-reported urinary incontinence severity as measured by the International Consultation on Incontinence questionnaire-short form (ICI-Q). This short and simple questionnaire is used to screen for incontinence (urine leakage) to obtain a brief yet comprehensive summary of the level, impact and perceived cause of symptoms of incontinence. The ICI-Q consists of four questions and numeric scales: 1. How much do you leak urine? (0-5); never - all the time, 2. How much urine do you usually leak? (0-6); none - large amount, 3. Overall, how much does leaking urine interfere with your everyday life? (0-10); not at all - a great deal, 4. When does urine leak? Multiple choices. The ICI-Q score is the sum of questions 1-3 and ranges from 0-21. The higher the score, the greater severity of incontinence. Baseline data is compared to the 3 month data for the primary outcome. | Baseline and 3 months | |
Secondary | Group Behavioral Treatment Cost-effectiveness | Measure resource use and utilities and compare the difference in incontinence management costs and utilities between treatment and control group. | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT00523068 -
Pharmacological vs Surgical Treatment for Mixed Incontinence
|
Phase 4 | |
Completed |
NCT00904969 -
A Pre-Market Study of the American Medical Systems (AMS) Transobturator Male Sling System for the Treatment of Male Stress Urinary Incontinence
|
N/A | |
Completed |
NCT00190827 -
Effectiveness of Duloxetine in the Treatment of Stress Urinary Incontinence(Uncontrolled Leakage of Urine)
|
Phase 3 | |
Completed |
NCT00190814 -
Effectiveness and Safety of Duloxetine in Women Experiencing Urinary Leakage Due to Physical Stress and Urge.
|
Phase 3 | |
Terminated |
NCT00247286 -
Weighted Vaginal Cones Versus Biofeedback in the Treatment of Urodynamic Stress Incontinence: a Randomized Trial.
|
Phase 4 | |
Completed |
NCT01959347 -
Combined Treatment for Mixed Incontinence
|
Phase 3 | |
Completed |
NCT00244296 -
To Determine How Effective Duloxetine is in Treating Women 65 Years and Older With Symptoms of Stress Urinary Incontinence, or With a Combination of Stress Urinary Incontinence and Urge Urinary Incontinence Symptoms
|
Phase 4 | |
Not yet recruiting |
NCT05570071 -
A Study of the Use of Vaginal Radiofrequency Therapy in Treatment of SUI.
|
N/A | |
Completed |
NCT02334878 -
Stem Cell Therapy for Treatment of Female Stress Urinary Incontinence
|
Phase 3 | |
Completed |
NCT01382602 -
Autologous Muscle Derived Cells Female Stress Urinary Incontinence Clinical Study
|
Phase 3 | |
Completed |
NCT03296462 -
Hip External Rotation Physical Therapy Trial
|
N/A | |
Recruiting |
NCT02750878 -
Surgical Consent Process for Trans-obturator Tape Slings.
|
N/A | |
Completed |
NCT02296099 -
Trial Liposomal Bupivacaine Following Retropubic Suburethral Sling for Stress Urinary Incontinence
|
Phase 4 | |
Completed |
NCT02599051 -
Transobturator Verus Single Incision Slings
|
N/A | |
Completed |
NCT00138749 -
An 8 Week Study Looking At The Efficacy, Toleration And Safety Of SS-RBX For Stress Urinary Incontinence.
|
Phase 2 | |
Terminated |
NCT03614611 -
Canadian Experience With Contiform Intravaginal Device For The Treatment Of Stress Incontinence
|
N/A | |
Completed |
NCT03722719 -
The Knack on Female Stress Urinary Incontinence
|
N/A | |
Active, not recruiting |
NCT02275728 -
Pelvic Floor Muscle Training With and Without Biofeedback in Women With Stress Urinary Incontinence
|
N/A | |
Terminated |
NCT01358214 -
Quality of Life After Tension Free Transvaginal Sling / Tape Operation With a Titanized Surgical Tape (TiLOOP® Tape)
|
N/A | |
Active, not recruiting |
NCT01323426 -
Treatment of Stress Urinary Incontinence by Injection of Autologous Muscle Fibers Into the Urethral Sphincter.
|
Phase 1/Phase 2 |